BIO accuses insurer report of shifting blame on drug prices
BioPharma Dive: Biotech and Pharma news | May 04, 2017
BIO, a major biotech trade group, is pushing back against a new report showing steady prescription drug price increases over the past seven years, claiming the "cherry-picked" findings don't accurately reflect market dynamics.